Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

11
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
11
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

51
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
51
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

997
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
997
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

10
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
10
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

21
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
21
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of new antithrombotic drugs for children (part 1): guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group.

Journal of thrombosis and haemostasis : JTH·2026
Same author

ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.

Blood advances·2026
Same author

Systematic review on the design and methodology of the pediatric direct oral anticoagulant clinical trials for thrombosis prevention: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy.

Journal of the American Heart Association·2026
Same author

Enhanced trial efficiency of the novel "contemporaneous control recapture" parallel-cohort RCT design: Methods and application in the CRITICAL-Kids-TP trial.

Contemporary clinical trials·2025
Same author

Benchmarking prophylaxis with factor concentrates: reference data on annualized bleeding rates in children with severe hemophilia.

Haematologica·2025

Related Experiment Video

Updated: Oct 6, 2025

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

946

Anticoagulation in Pediatric Patients.

Christoph Male1

  • 1Department of Paediatrics, Medical University of Vienna, Vienna, Austria.

Hamostaseologie
|January 18, 2022
PubMed
Summary

Direct oral anticoagulants (DOACs) offer a promising alternative for pediatric anticoagulation, addressing limitations of traditional therapies. Approved for specific uses, they demonstrate comparable safety and efficacy without requiring routine monitoring.

Area of Science:

  • Pediatric Hematology
  • Pharmacology
  • Thrombosis Management

Background:

  • Pediatric anticoagulation presents unique challenges including evolving coagulation systems and drug pharmacokinetics.
  • Traditional anticoagulants in children often require frequent monitoring, posing practical difficulties.
  • Direct oral anticoagulants (DOACs) possess properties making them suitable for pediatric use.

Purpose of the Study:

  • To review the development and application of DOACs in pediatric anticoagulation.
  • To highlight the advantages of DOACs over traditional anticoagulants in children.
  • To discuss ongoing research and future directions for DOACs in pediatric thrombosis.

Main Methods:

  • Review of pediatric development programs for DOACs.

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

821
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

1.1K

Related Experiment Videos

Last Updated: Oct 6, 2025

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

946
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

821
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

1.1K
  • Analysis of child-appropriate formulations and age-specific dosing.
  • Evaluation of safety and efficacy data from ongoing Phase 3 trials.

    • Main Results:

    • Rivaroxaban and dabigatran are authorized for pediatric treatment and extended prevention of venous thrombosis.
    • DOACs show comparable safety and efficacy to standard anticoagulants in children.
    • No routine monitoring is required for authorized DOACs in pediatric patients.

    Conclusions:

    • DOACs represent a significant advancement in pediatric anticoagulation, offering improved convenience and safety.
    • Further research and real-world data are needed to expand DOAC use in younger children and specific populations.
    • Pediatric authorizations for additional DOAC indications, such as primary prevention in high-risk settings, are anticipated.